More about Bayer CropScience Limited
Fundamentals for Bayer CropScience Limited
Regulatory Filings for Bayer CropScience Limited
IndiGo Implements Steep Fuel Surcharge as Iran Conflict Sends Jet Fuel Costs Soaring
The RBI's New Forex Fortress: Defensive Maneuvers in an Era of Oil Shocks
India's Fiscal Milestone: GST Collections Breach ₹2 Lakh Crore Mark for the First Time
AI Disruption Accelerates: Oracle Layoffs Raise Alarms for India’s Tech Workforce
Fundamentals for Bayer CropScience Limited
Business Operations:
Sector: Basic MaterialsIndustry: Agricultural Inputs
Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRise and other digital applications, such as drones for spray services, etc., as well as provides various technologies, such as remote sensing, IoT sensors, GPS, artificial intelligence, and data analytics to monitor and manage crop growth, soil quality, weather patterns, and other factors. The company also exports its products. Bayer CropScience Limited was founded in 1863 and is based in Thane, India.
Revenue projections:
BAYERCROP is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 28.443815 |
| debtToEquity | 3.266000 |
| earningsGrowth | 1.798000 |
| revenueGrowth | 0.047000 |
| grossMargins | 0.395060 |
| operatingMargins | 0.092480 |
| trailingEps | 149.280000 |
| forwardEps | 168.753740 |
BAYERCROP's Forward PE ratio is in a good range, reflecting a reasonable balance between stock price and earnings. The stock is not overpriced, leaving room for growth, which suggests potential for investors looking to capitalize on future value appreciation.
Bayer CropScience Limited's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.
Price projections:
BAYERCROP's price projections have steadily declined, indicating that analysts are revising their outlook on the company. This downward trend reflects a more cautious perspective on BAYERCROP's future growth prospects.
Recommendation changes over time:
The recent buy bias for BAYERCROP from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see BAYERCROP as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
U.S. Labor Market in 2026: JOLTS and Consumer Confidence Reveal Why Hiring Cooled Without Unemployment Spike
Lending Unleashed: Assessing the Impact of the Federal Reserve’s Capital Rollback
Calendar Collision: How Mahavir Jayanti's Overlap With Fiscal Year-End Reshapes India's Tax-Loss Harvesting Landscape